Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
438 Despite their promise, mTOR inhibitors have shown limited progress in the treatment of metabolic diseases owing to side effects such as hyperlipidemia, diabetes, and impaired wound healing, 439 limiting broader application in patients with metabolic comorbidities
The same principle applies when converting from semaglutide to tirzepatide or when transitioning between compounded and brand-name formulations
Additional information Competing interest The authors declare that they have no competing interests
Compounded versions of the drugs are easily accessible and affordable for most patients
No pain, no burning, no swelling, and no side effects
Tirzepatide is sold as Mounjaro for diabetes and Zepbound for obesity, again the same drug under different names
